Integral Derivatives’s Pacific Biosciences PACB Stock Holding History

Integral Derivatives’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-10,746	Closed	-$28K	–	913
2017 Q4	$28K	Buy	+10,746	New	+$37.6K	﹤0.01%	1083
2017 Q1	–	Sell	-14,758	Closed	-$56K	–	1320
2016 Q4	$56K	Buy	+14,758	New	+$107K	﹤0.01%	1084

Other funds holding PACB

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

RCM

Raging Capital Management Rocky Hill, New Jersey $18.2M AUM 17.75% 1-Year Est. Return

Integral Derivatives's PACB Position: Q1 2018 in Review

Integral Derivatives sold out of Pacific Biosciences (PACB) in Q1 2018, closing a stake of 10,746 shares — an estimated $28K sold.

Integral Derivatives first reported a position in PACB in Q4 2016 and held it in 2 quarters. The position peaked at $56K in Q4 2016. 101 funds tracked by Wall St. Rank hold PACB as of Q1 2018.

Integral Derivatives reported no remaining Pacific Biosciences position as of Q1 2018 after selling out during the quarter.
Integral Derivatives sold 10,746 Pacific Biosciences shares in Q1 2018, an estimated $28K.
Integral Derivatives first reported a position in Pacific Biosciences in Q4 2016 and held it in 2 quarters.
Integral Derivatives's Pacific Biosciences position peaked at $56K in Q4 2016.
101 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2018.

Based on Integral Derivatives's 13F filing for Q1 2018, filed 19 Apr 2018.